Literature DB >> 25022639

Effectiveness of omalizumab in severe persistent asthma under real-life conditions.

Anthony D D'Urzo1, Jenny Wong2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25022639      PMCID： PMC4096265     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  7 in total

1.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.

Authors:  E F Juniper; G H Guyatt; R S Epstein; P J Ferrie; R Jaeschke; T K Hiller
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

2.  Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults.

Authors:  M D Lougheed; C Lemière; S D Dell; F M Ducharme; J Mark Fitzgerald; R Leigh; C Licskai; B H Rowe; D Bowie; A Becker; Louis-Philippe Boulet
Journal:  Can Respir J       Date:  2010 Jan-Feb       Impact factor: 2.409

3.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

4.  Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Authors:  S T Holgate; A G Chuchalin; J Hébert; J Lötvall; G B Persson; K F Chung; J Bousquet; H A Kerstjens; H Fox; J Thirlwell; G Della Cioppa
Journal:  Clin Exp Allergy       Date:  2004-04       Impact factor: 5.018

5.  Global strategy for asthma management and prevention: GINA executive summary.

Authors:  E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

6.  "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

Authors:  G Brusselle; A Michils; R Louis; L Dupont; B Van de Maele; A Delobbe; C Pilette; C S Lee; S Gurdain; S Vancayzeele; P Lecomte; C Hermans; K MacDonald; M Song; I Abraham
Journal:  Respir Med       Date:  2009-07-19       Impact factor: 3.415

7.  Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

Authors:  A M Vignola; M Humbert; J Bousquet; L-P Boulet; S Hedgecock; M Blogg; H Fox; K Surrey
Journal:  Allergy       Date:  2004-07       Impact factor: 13.146
  7 in total
  1 in total

1.  Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.

Authors:  Jing Li; Jian Kang; Changzheng Wang; Jing Yang; Linda Wang; Ioannis Kottakis; Michael Humphries; Nanshan Zhong
Journal:  Allergy Asthma Immunol Res       Date:  2016-07       Impact factor: 5.764
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.